MONDAY 18TH MAY

HALL 3 HALL 4 HALL 11C - cap 95 HALL 11B 9.00 Symposium Registration 09.30 - 10.15 Evolution of PRRT Therapy - sponsored by AAA 10.00 - 10.25 Bootcamp Registration & refreshments in foyer BREAKFAST SYMPOSIUM 10.25 - 10.30 Welcome Dr J Buscombe 10.30 - 12.00 Bootcamp Session 1 NETS 10.30 - 12.00 Bootcamp Session 2 Regulations and 10.30 - 12.00 RTN Bootcamp Session 1 - Advanced Practice for RTNs risk assessments Chairs: TBC Chairs: TBC Chairs: TBC 10.30 - 10.35 Introduction 10.30 - 11.00 ONR - transport regs. 10.30 - 11.00 Advanced Practice in Therapies Dr Simon Hughes Simon Clark Sarah Atkinson University Birmingham Office for Nuclear Regulation Newcastle Hospitals 10.35 - 10.55 Overview of Clinical Management of NET 11.00 - 11.30 HSE 11.00 - 11.30 Advanced Practice in Nuclear Cardiology Dr Tahir Shah Karen Fuller Mark McDade Queen Elizabeth Birmingham Health and Safety Executive Glasgow Royal Infirmary 10.55 - 11.15 Range of systemic therapies available for NET management 11.30 - 12.00 Inspector Calls 11.30 - 12.00 Nurse practitioner Prescribing

Dr Ian Geh Dr Julie Speakman Liz Garth University Hospitals Birmingham Royal Derby Hospital Salford University 11.15 - 11.35 Pathology of NET tumours in diagnosis and management.

Dr Mona ElElshafie

11.35 - 11.55 CT and MR imaging in the management of NET Dr Hulya Weissman Aintree Hospital, Liverpool 12.00 - 12.30 Refreshment break in EXHIBITION HALL Refreshment break 12.30-13.30 Bootcamp Session 3 Bootcamp Session 4 Practical dose RTN Bootcamp Session 2 - Non-Medical Reporting calculations for risk assessments Chairs: TBC Chairs: TBC Chairs: TBC 12.30 - 12.50 Octreotide imaging in the multi staging imaging of NET 12.30 - 12.55 Talk Title TBC 12.30 - 13.00 Pathway to Becoming a Non-Medical Reporter in tumours Nuclear Medicine Prof. Sobhan Vinjamuri Matt Memmott Jo Weekes Royal Liverpool Hospital, Liverpool Royal Wolverhampton Hospital 12.50 - 13.10 DOTApeptide imaging in the multi staging imaging of NET 12.55 - 13.20 Talk Title TBC 13.00 - 13.30 Basics of Non-Medical Reporting tumours Dr Shaunak Navalkissoor Bill Thomson Sarah Stace Royal Free Hospital, Hywel Dda Health Board, Pembrokeshire Wales 13.10 - 13.30 Expert panel discussion of complex cases 13.20 - 13.30 Discussion Dr Simon Hughes University Hospitals Birmingham 13.30 - 14.30 Lunch break exhibition hall Lunch break Lunch break Lunch break 13.45 - 14.15 Poster judging Exhibition Hall 14.15 Welcome Dr J Buscombe 14.30 -16.00 Session 1 - Artificial Intelligence 14.20 - 16.20 SESSION 3 - YIP 14.30 - 16.00 MRT TRAINING SESSION 1 14.30 - 15.00 Invited Presentation

Chairs: TBC Chairs: TBC Chairs:TBC 14.30 - 15.00 Clinical applications of artificial intelligence algorithms in 14.20 - 14.40 1 - [18F] (FCH) PET/CT in 14.30 - 14.40 Introduction to therapy types & theranostics 14.30 - 15.00 Education & Practice of Nuclear Medicine in Portugal: nuclear cardiology persistent/recurrent primary (131I –thyroid Ca, mIBG, PSMA, DOTATATE, overview and challenges Dr Piotr Slomka hyperparathyroidism SIRT) Pedro Costa Cedars-Sinai Medical Center, Los Angeles, California Mitesh Naik, Sairah Khan, Neva Patel, Dr Daniel McGowan ESS Porto, Portugal Laura Perry, Ali Alsafi, Chris Harvey, Luis Churchill Hospital, Oxford Alves, Fausto Palazzo, Tara Barwick Imperial College Healthcare NHS Trust, London, United Kingdom

15.00 - 15.30 TexRAD Texture (Radiomics) analysis of imaging data - ready 14.40 - 15.00 2 - Impact on SPECT Reconstruction of 14.40 - 14.50 Introduction to MIRD 15.00 - 16.00 RTN Session 1: Implementing New Technologies in for routine clinical use Iterative Metal Artefact Reduction Mr Bruno Rojas-Fisher Nuclear Medicine Dr Balaji Ganeshan Lauren Urquhart, Colin Brown, Sandy Small Royal Marsden Hospital Chairs: TBC Global Business Development Director at Feedback Medical Ltd Gartnavel General Hospital, Glasgow, United Kingdom

15.30 - 16.00 Exploring PET-CT services internationally: an International 15.00 - 15.20 3 - Radioiodine I-131 therapy: A service 14.50 - 15.00 Data acquisition 15.00 - 15.30 Procurement to productivity - a SPECT/CT journey Cancer Benchmarking Partnership (ICBP) perspective evaluation of clinical outcome, patient Ms April-Louise Smith Lubna Hussain Ms Charlotte Lynch experience and compliance with Institute of Nuclear Medicine, UCLH Cancer Research UK protocol Shaun Johns1, Jilly Croasdale1, Alp Notghi2 1Birmingham City Hospital, Radiopharmacy, Birmingham, United Kingdom. 2Birmingham City Hospital, Nuclear Medicine, Birmingham, United Kingdom 15.20 - 15.40 4 - Validation of the Siemens e7-tools 15.00 - 15.10 Data processing 15.30 - 16.00 Experience of a new generation PET/CT – first off-line PET image reconstruction Mr Matthew Aldridge impressions software UCLH Virginia Espanola George Needham1,2, Christopher University College Hospital Oldfield3, Peter Julyan2, Dave Cullen1, Jose Anton-Rodriguez2,3, Ian Armstrong3, Bal Sanghera4 1University of Manchester, Manchester, United Kingdom. 2The Christie NHS Foundation Trust, Manchester, United Kingdom. 3Manchester University NHS Foundation Trust, Manchester, United Kingdom. 4Paul Strickland Scanner Centre, Mount Vernon Hospital, Northwood, United Kingdom

15.40 - 16.00 5 - The clinical utility of [18F]FDG - 15.10 - 16.00 Workshop - whole body monitoring PET/CT in MDR-TB patients with Dr Jill Tipping residual CT abnormalities The Christie Hospital, Manchester Mirae Park1,2, Dijay Dave3, Georgina Russell1, Laura Martin1, Ajit Lalvani2, Onn Min Kon1,4 1Imperial College Healthcare NHS Trust, London, United Kingdom. 2National Institute for Health Research, , London, United Kingdom. 3Imperial College London, London, United Kingdom. 4National Heart and Lungs Institute, London, United Kingdom 16.00 - 16.20 6 - Multi-modality Diagnostic Characterization of [18F]FDG-avid Thyroid Incidentalomas in relation to the British Thyroid Association Guidelines Sabyasachi Bandyopadhyay1, Achuth Hosur1, Kimberly Allan1, Ting Ting Zhang1, Charles Sayer1, James Hunter2, Mark Aplin1, Nitasha Singh1, Sabina Dizdarevic1,3 1Brighton & Sussex University Hospital NHS Trust, Brighton, United Kingdom. 2Clinical Imaging Science Centre, University of Sussex and Brighton, Brighton, United Kingdom. 3Clinical Imaging Science Centre, Brighton & Sussex Medical School, University of Sussex and Brighton, Brighton, United Kingdom 16.00 - 16.30 Refreshment break EXHIBITION HALL 16.20 - 16.30 Refreshment break Refreshment break Refreshment break 16.30 - 18.00 SESSION 2 - Recent Advances in Molecular Radiotherapy 16.30 - 17.56 SESSION 4 - Neurology 16.30 - 18.00 MRT TRAINING SESSION 2 16.30 - 18.00 RTN Session 2: PET/CT for use in radiotherapy Chairs: TBC Chairs: TBC Chairs: TBC 16.30 - 17.00 , Radioembolisation and Radiobiology 16.30 - 16.55 Brain imaging for the early diagnosis of 16.30 - 17.15 Workshop (SIRT) 16.30 - 17.00 Ros Breen Fund: Report from Funding Recipient Prof Katherine Vallis those with and at risk of dementia Miss Allison Craig Monica Martins Churchill Hospital Prof John O'Brien Royal Marsden Hospital Singleton Hospital Wales University of Cambridge School of Clinical Medicine

17.00 - 17.30 Radioligand therapy using Ac-225 PSMA 16.55 - 17.06 7 - Emerging role of [18F]- 17.15 - 18.00 Workshop (SPECT dosimetry) 17.00 - 17.30 Practicalities of PET/CT imaging for radiotherapy Prof Mike Sathekge PET/CT in assessment and Mr Matthew Aldridge treatment planning University of Pretoria, South Africa management of people living with HIV UCLH Giorgio Testanera and subjective cognitive impairment. Barts Health London Nicolas Eftychiou1, Jaime Vera1, Henryk Barthel2, Matti Shuerer2, Michael Rullman2, Osama Sabri2, Ana Andrade3, Johan Lijla4, Helena McMeekin5, Mark Aplin1, Sabina Dizdarevic1,3 1Brighton and Sussex University Hospitals, Brighton, United Kingdom. 2University of Leipzig, Leipzig, Germany. 3Clinical Imaging Science Centre,, Brighton, United Kingdom. 4Hermes Medical Solutions, Stockholm, Sweden. 5Hermes Medical Solutions, London, United Kingdom

17.06 - 17.17 8 - Can pain perception be measured by 17.30 - 18.00 Planning radiotherapy treatments using PET/CT a PET/CT brain scan after spinal cord Lucy Faulkner stimulation? Singleton Hospital Wales Helena McMeekin1,2, Arman Parsai1, Maria Burniston1, Alia Ahmad3, Kavita Poply3, Vivek Mehta3 1Nuclear Medicine Dept., Barts Health NHS Trust, London, United Kingdom. 2Hermes Medical Solutions Ltd., London, United Kingdom. 3Pain & Anaesthesia Research Centre, Barts Health NHS Trust, London, United Kingdom 17.17 - 17.28 9 - Interobserver Variability in the Qualitative and Quantitative Analysis of Cardiac MIBG for the Diagnosis of Lewy Body Disorders Rob Foley1, Chris Green1, Isabel Laurence2, Stewart Redman1, Richard Graham1, David Little1 1Royal United Hospital, Bath, United Kingdom. 2Southmead Hospital, North Bristol NHS Foundation Trust, Bristol, United Kingdom

17.28 - 17.39 10 - An investigation of follow up quantitative imaging in patients with early/ balanced loss on initial ioflupane studies. Harini Fernando1,2, Amy Eccles2,1 1Kings College, London, United Kingdom. 2Guys and St Thomas' Trust, London, United Kingdom 17.39 - 17.50 11- Quantification for DaTSCAN: can it change you reports and add confidence? Alp Notghi, Mohamed El-Sayed, Terence Jones, Joseph O'Brien Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom

17.50- 18.01 12 - 2ND PLACE STUDENT PRIZE Improvement of [18F]FDG PET/CT and MRI concordance in Temporal Lobe Epilepsy Pre-surgical Assessment using Statistical Parametric Mapping Z- scores Marie Kershaw1, Lu Yiping2, Vijay Sawlani1, Hayaka Amada3, Simon Hughes4 1University of Birmingham, Birmingham, United Kingdom. 2Fudan University, Shanghai, China. 3City Hospital, Birmingham, United Kingdom. 4University Hospitals Birmingham, Birmingham, United Kingdom 18.00 - 19.30 President's reception - Exhibition Hall 19.30 Close Close Close TUESDAY 19TH MAY

HALL 3 HALL 4 HALL 11C HALL 11B 8.30 REGISTRATION OPENS 09.00 - 9.30 AGM Medics - ARSAC update - Kevin 09.00 - 9.30 Clinical Scientists AGM 09.00 - 9.30 RTNG AGM: Chair Nick Gulliver Bradley & Louise Fraser 9.30- 11.00 SESSION 5 - SPECT-CT masterclass 9.30 - 11.00 session 6 - renal basic science - abstracts 09.30- 11.00 SESSION 7 PET-CT in radiotherapy 9.30 - 11.00 RTN Session 3: Update on Radiation Protection masterclass Chairs: TBC Chairs: TBC Chairs: TBC Chairs: TBC 9.30 - 10.00 SPECT/CT in children: experience from a 9.30 - 9.41 15 - The effect of protein binding on calculated 9.30 - 10.00 Clinical and research applications of PET in 9.30 - 10.00 Radiation Protection in PET-CT paediatric tertiary referral centre glomerular filtration rates using [99mTc]Tc- radiotherapy Daniela Fonseca Dr Lorenzo Biassoni DTPA: identifying, quantifying and options to Dr Marlene Fischer Invicro Great Ormond Street Hospital resolve the issue. St Thomas' Hospital Sam Townrow, Natalie Sizer, Maria Burniston Barts Health NHS Trust, London, United Kingdom

10.00 - 10.30 SPECT/CT in orthopedics 9.41 -9.52 16 - An alternative to Brochner-Mortensen 10.00 - 10.30 Research applications focusing on PET- 10.00 - 10.30 Radiation Protection in Radionuclide Therapy Dr Daniela Miladinova correction in slope-intercept GFR measurement guided treatment in head and neck cancer in Carla Abreu and Lucy McAreavey University Sv Kiril i Metodij with no requirement for prior body size scaling the UK Royal Marsden NHSFT Helena McMeekin1, Maria Burniston1, Mark Dr Delali Adjogatse Barnfield2, A. Michael Peters3,4 King's College London 1Barts Health NHS Trust, London, United Kingdom. 2St James’s University Hospital, Leeds, United Kingdom. 3King’s College Hospitals, London, United Kingdom. 4Molecular Imaging Centre, Harley St, London, United Kingdom

10.30 - 11.00 Subject of SPECT-CT Quantification 9.52 - 10.03 17 - Feasibility of ‘Standardless’ GFRs 10.30 - 11.00 Guidance on the use of PET for treatment 10.30 - 11.00 Radiation Protection in Radiopharmacy Dr Stefan Voo Nicholas Bird, Efstathios Varzakis planning in radiotherapy clinical trials Denise Aniceto University College London Addenbrooke's Hospital, Cambridge, United Ms Lucy Pike Royal Marsden NHSFT Kingdom King's College London

10.03 - 10.14 18 - An Audit of Renal Transplant Perfusion Index processing for renogram studies Helena McMeekin1,2, Maria Burniston1 1Barts Health NHS Trust, London, United Kingdom. 2Hermes Medical Solutions Ltd., London, United Kingdom 10.14 - 10.25 19 - Counting a Glomerular Filtration Rate Study on a Gamma Camera: A Proof of Concept James Gray1, Alex Smout1, Lisa O'Brien2 1Royal Surrey County Hospital, Guildford, United Kingdom. 2St. Richard's Hospital, Chichester, United Kingdom 10.25 - 10.36 20 - Maximum acceptable delay in processing [99mTc]Tc-DTPA GFR plasma samples Laura Perry1, David Woodhouse2, Michael Woodward1, Zarni Win2, Kuldip S Nijran1 1Radiological Sciences Unit, Imperial College Healthcare NHS Trust, London, United Kingdom. 2Nuclear Medicine Department, Imperial College Healthcare NHS Trust, London, United Kingdom 10.36 - 10.45 21 - Can patient age be used to decide the optimum sample time for single sample GFR studies? Alexander Smout, James Scuffham Royal Surrey County Hospital, Guildford, United Kingdom 11.00 - 11.30 Refreshment break 11.00 - 11.30 Refreshment break IN COTSWOLD Refreshment break 11.30 - 13.00 SESSION 8 - ABC Imaging 11.30 - 13.00 SESSION 9 - Physics Technological advances 11.30 - 13.00 SESSION 10 Cardiac 11.30 - 13.00 RTN Session 4: Proffered papers

Chairs: TBC Chairs: TBC Chairs: TBC Chairs: TBC 11.30 - 12.00 PET imaging of cerebral ABC transporters 11.30 - 11.41 22 - A feasibility study for half time [99mTc]Tc- 11.30 - 11.55 Molecular Cardiovascular Imaging: Current 11.30 - 11.41 48 - Evaluation of radioisotope injection technique for in healthy ageing and Alzheimer’s disease MDP whole body bone imaging Status and Future Directions sentinel lymph node biopsy in breast cancer. Dr Oliver langer Emily Fittock, Clare Beadsmoore, Andoni Toms, Prof Divaker Jain Rhys Morris1, Andrew Tootell2, John Thompson2 University of Vienna Ramona-Rita Sultana, David Newman, Davina New York Medical College, Westchester 1Ysbyty Gwynedd, Bangor, United Kingdom. 2Salford Pawaroo, Matthew Gray Medical Center University, Salford, United Kingdom The Norfolk and Norwich University Hospitals NHS Valhalla NY Foundation Trust, Norwich, United Kingdom

12.00 - 12.30 Imaging the function and expression of 11.41 - 11.52 23 - Can we reduce our Bone SPECT-CT 11.55 - 12.20 Interesting and Challenging Cases in 11.41 - 11.52 49 - A service evaluation of SmartVent™ administered ABC transporters in drug resistance acquisition time to half? Cardiovascular Nuclear Imaging [99mTc]Tc-DTPA during SPECT/CT VQ imaging Dr Pavitra Kannan Mohamed El-Sayed, Joseph O'Brien, Terence Prof Divaker Jain James Elliott1,2, Tristan Barnden2, Alexis Corrigan2 University of Oxford Jones, Anthony D'Sa, Alp Notghi New York Medical College, Westchester 1Canterbury Christ Church University, Canterbury, United Sandwell & West Birmingham Hospitals NHS Trust, Medical Center Kingdom. 2Maidstone Hospital Nuclear Medicine Department, Birmingham, United Kingdom Valhalla NY Maidstone, United Kingdom

12.30 - 12.41 13 - Towards imaging cisplatin resistance 11.52 - 12.03 24 - Feasibility and optimisation of half-time or 12.20 - 12.31 38 - The use of Radionuclide 11.52 - 12.03 50 - Optimising staff and facilities in [177Lu] Peptide with 64Cu PET half-dose [99mTc]Tc-MDP bone SPECT using Ventriculography in assessing Herceptin Receptor Radionuclide Therapy (PRRT) to allow two Fahad Al-salemee, Joanna Bartnicka, Siemens Flash3D image reconstruction treatment in Breast cancer patients to be treated on the same day as day case Timothy Witney, Philip Blower Dominyka Ivanova1, Nicolas Eftychiou2, Haseeb Ann Tweddel1, Emmanouil Papadopoulos1, admissions. King's College London, London, United Ahmed2, Lefteris Livieratos 2 Glenn Woolley1, Imran Sunderji1, Matthew Sandra Johns, Sofia Michopoulou, Francis Sundram, Ziauddin Kingdom 1King's College London, London, United Kingdom. Balerdi1, Penny O'Neill1, Michael Lind2 Saad, Jayne Harris 2Guy's & St Thomas' NHS Foundation Trust, 1Hull University Teaching Hospitals NHS Trust, University Hospitals Southampton NHS Foundation Trust, London, United Kingdom East Yorkshire, United Kingdom. 2Hull York Southampton, United Kingdom Medical School, Hull, United Kingdom

12.41 - 12.52 14 - Approaches of PET metallomics for 12.03 - 12.14 25 - Dual-isotope SPECT/CT Imaging: 12.31 - 12.42 39 - Evaluation of adverse cardiac event 12.03 - 12.14 51 - VQ Service evaluation to assist PE diagnosis in the study of metal trafficking in vivo A study on the optimisation and impact of rates in the 5 years following normal pregnancy. George Firth1, Zilin Yu1, Joanna Bartnicka1, clinically available artefact reduction myocardial perfusion imaging using the Lidia Jasinska, Sandra Johns, Phillipa Williams, Timothy Fahad Al-salamee1, Hannah Greenwood1, techniques Digirad Cardius X-ACT Melhuish, Ziauddin Saad, Francis Sundram Jana Kim1, David Parker2, Philip Blower1 Michael Woodward1, Laura Perry1, William Monique Vekeria1, Christopher Green2, Isabel University Hospital Southampton, Southampton, United 1King's College London, London, United Svensson2, Joy Murrell2, Kuldip Nijran1 Laurence1 Kingdom Kingdom. 2University of Birmingham, 1Radiological Sciences Unit, Imperial College 1North Bristol NHS Trust, Bristol, United Birmingham, United Kingdom Healthcare NHS Trust, London, United Kingdom. Kingdom. 2Cheltenham and Gloucester NHS 2Nuclear Medicine, Imperial College Healthcare Trust, Cheltenham, United Kingdom NHS Trust, London, United Kingdom 12.14 - 12.25 26 - The impact of SiPM PET/CT scanners. A 12.42 - 12.53 40 - Coronary artery [18F]- 12.14 - 12.25 52 - Regadenoson rescue of failing physiological stress: step change in practice? positron emission tomography and USPIO- an evolving safety profile/impact on scan quality. Sarah J McQuaid, April-Louise Smith, Anna Barnes, enhanced magnetic resonance angiography Robin Mark McDade1, Barbara Kerr2, Scott Allan1, Craig Catherine J Scott, Alexandra Mackenzie, John C identifies culprit lesions in myocardial Paterson1, Nicholas Goodfield1 Dickson infarction 1Glasgow Royal Infirmary, Glasgow, United Kingdom. Institute of Nuclear Medicine, University College Marwa Daghem1, Rishi Ramaesh,2, Gillian 2Glasgow Royal Infirmary, Glasgow, United States Minor London Hospitals, London, United Kingdom Macnaught,3, Scott Semple3, Edwin J R van Outlying Islands Beek4, Marc Dweck1, Dave Newby1, Michelle Williams5 1Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. 2NHS Lothian, Edinburgh, United Kingdom. 3Edinburgh Imaging facility QMRI, University of Edinburgh, Edinburgh, United Kingdom. 4Edinburgh Imaging facility QMRI, Edinburgh, United Kingdom. 5University of Edinburgh, Edinburgh, United Kingdom 12.25 - 12.36 27 - Use of the CT scout view (topogram) for 12.53 - 13.04 41 - The potential impact of incidental 12.25 - 12.36 53 - How do Nuclear Medicine Radiographers and accurate attenuation correction and cardiac uptake during routine bone scans Technologists Understand the Concept of Patient Care? quantification of nuclear medicine planar on a cardiac amyloidosis service. Andrew Cheetham1,2, Beverly Gray2, Sara Soares2, Jay images: Patient Data Dean Manning1, Thomas Butler2, Megan Dave2, Rosalind Pliszka2, Nick Gulliver2 Gregory James, Joseph O'Brien, Bill Thomson Butler2, Yasir Majeed1, Robert Gordon1, Ganwa 1King's College, London, London, United Kingdom. 2King's City Hospital, Birmingham, United Kingdom Qadir1, Sayed Kazi1, Rhys Beynon1, Anik College Hospital NHS Foundation Trust, London, United Appaji1, Ash Patwala1, Duwarakan Kingdom Satchithananda1, David Bailey1 1UHNM NHS Trust, Stoke-on-Trent, United Kingdom. 2Student, Stoke-on-Trent, United Kingdom

12.36 - 12.47 28 - 3RD PLACE STUDENT PRIZE Bayesian 12.36 - 12.47 54 - Striving for Radiographer autonomy –investigation of Penalised Likelihood (Q.Clear) reconstruction the benefits to a small NHS trust of [68Ga]DOTATATE PET/CT in neuroendocrine Lindsay Watkinson tumours: a comparison with standard image Warrington and Halton Teaching Hospitals NHS Foundation reconstruction methods Trust, Warrington, United Kingdom Rachna Prem1, James Temple1, Wei-Shern Chen2, Krokos Georgios2, Gary Cook2 1GKT School of Medicine, London, United Kingdom. 2King's College London, London, United Kingdom

12.47 - 12.58 29 - Looking at [18F]FDG PET with 2020 Vision 12.47 - 12.58 55 - The Optimal Timing of the SeHCAT Scan in the Chris Mathews, Ian Armstrong Diagnosis of Bile Acid Malabsorption for Patients with MUFT, Manchester, United Kingdom Chronic Diarrhoea Gerard McKiernan Belfast Health and Social Care Trust, Belfast, United Kingdom

13.00 - 13.30 BNMS AGM in Hall 3 with lunch 13.00 - 14.00 lunch 13.15 - 13.45 Poster judging Exhibition Hall 14.00 - 15.00 ANNUAL LECTURE - ARTURO CHITI Chairs: TBC 15.00 - 15.45 Innovation and Education Showcase Chairs: TBC 15.00 - 15.05 Introduction 15.05-15.25 Traceability and Standardisation in Nuclear Medicine Imaging and Therapy Dr Andrew Robinson National Physical Laboratory

15.25-15.35 Escan Academy - live demonstration 15.35-15.45 InnovativeMorten Hallager Prize and voting. 15.45 - 16.15 Refreshment break Refreshment break 16.15 - 17.45 Session 11 - Masterclass in thyroid 16.15-17.45 session 12 - Computational and phantom 16.15 - 17.45 SESSION 13 Radiopharmacy 16.15 - 17.45 RTN Session 5: PROFFERED PAPERS ii techniques Chairs: TBC Chairs: TBC Chairs: TBC Chairs: TBC 16.15 - 16.45 NICE guidelines for benign thyroid 16.15 - 16.26 30 - Justification for PERCIST reference 16.15 - 16.26 42 - Red blood cell volume measurement - 16.15 - 16.26 56 - Dopaminergic imaging of pituitary adenomas with disease regions using a semi-automated algorithm can Indium replace Chromium? [18F] PET/CT - an initial experience Dr Kristien Boelaert Luke Pleva1,2, Max Capel1,2, Heather Williams2, Alison Bolster, Gillian Ainslie-McLaren, Angela Ellie Knowler1, Alex Powles1, Lee Bartley1, Patrick Fielding1, University of Birmingham Peter Julyan2 Fee, June McKinstray, Alison Lee Aled Rees2, Chris Marshall1 1University of Manchester, Manchester, United Stobhill Hospital , Greater Glasgow and Clyde 1Wales Research and Diagnostic PET Imaging Centre, Kingdom. 2The Christie NHS Foundation Trust, Health Board, Glasgow, United Kingdom Cardiff University, Cardiff, United Kingdom. 2Neuroscience Manchester, United Kingdom and Mental Health Research Institute, Cardiff University, Cardiff, United Kingdom

16.45 - 17.15 Thyroid Cancer Theranostics: the 16.26 - 16.37 31 - Development and characterisation of a PET 16.26 - 16.37 43 - Optimisation of Cyclotron Production of 16.26 - 16.37 57 - Evaluation of the Image Quality in [68Ga]Ga-DOTA- Evolving Paradigm of Radioiodine “painting” robotic phantom to generate pseudo- [13N] Ammonia TOC – an initial approach Therapeutics anthropomorphic brain and geometric test Luiza Haberska, Steven Paisey, Andrew Clara Ferreira, James Cullis Prof Anca Avram objects under digital computer control Watkins, Christopher Marshall University Hospital of Coventry and Warwickshire, Coventry, Director, Nuclear Medicine Therapy Clinic, Anton Paramithas, Alan Britten Cardiff University, Cardiff, United Kingdom United Kingdom University of Michigan, Ann Arbor, USA St. George's Hospital, London, United Kingdom

16.37 - 16.48 32 - Assessing the improvement in lesion 16.37 - 16.48 44 - Optimising targeted radiolabelled 16.37 - 16.48 58 - The prevalence of CT truncation and impact on detectability on the Siemens Biograph Vision nanoparticles for radionuclide therapy rubidium-82 cardiac PET reconstructed with and without PET – a phantom study using a Channelised Rekaya Shabbir1, Marco Mingarelli2, Glenn TOF Hotelling Observer Flux3, Ananya Choudhury1, Tim Smith1 Raquel Gaspar1, Luís Freire2, Maria Clara Alves3, Ian S Christopher Oldfield1, Ian Armstrong2, Pete 1University of Manchester, Manchester, United Armstrong1 Julyan1, Bal Sanghera3 Kingdom. 2University of Aberdeen, Aberdeen, 1Manchester University NHS Foundation Trust, Manchester, 1The Christie NHS Foundation Trust, Manchester, United Kingdom. 3Royal Marsden NHS Trust, United Kingdom. 2ESTeSL, Lisbon, Portugal. 3Bradford Royal United Kingdom. 2Manchester University NHS Sutton, United Kingdom Infirmary, Bradford, United Kingdom Foundation Trust, Manchester, United Kingdom. 3Mount Vernon Hospital NHS Foundation Trust, Northwood, United Kingdom 16.48 - 16.59 33 - Variation of software platforms including 16.48 - 16.59 45 - Investigating the effect of sporicidal 16.-48 -17.48 RTN Session 6: Bone Imaging Agents: Principles and the use of in-house analysis in Nuclear disinfection step during the preparation of Recent Developments Medicine – results from a UK survey [99mTc] . Chairs: TBC Jonathan Price1, Mark Barnfield2, James Cullis3, Elizabeth Faminu1, Megan Longworth1, John Himsworth4, Gregory James5, Matthew Shazmeen Hansrod1, Fareeda Akhtar1, Memmott6, Anthony Murray7 Muhammad Ali1, Thomas Wan1, Sue Renn2, 1Southend University Hospital NHS Foundation Beverley Ellis1 Trust, Southend, United Kingdom. 2The Leeds 1Manchester University NHS Foundation Trust, Teaching Hospitals NHS Trust, Leeds, United Manchester, United Kingdom. 2Manchester Kingdom. 3University Hospitals Coventry and University, Manchester, United Kingdom Warwickshire NHS Trust, Coventry, United Kingdom. 4Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom. 5Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom. 6Manchester University NHS Foundation Trust, Manchester, United Kingdom. 7Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom

16.59 - 17.10 34 - Comprehensive validation of a Monte Carlo 16.59 - 17.10 46 - Validation of the use the Labnet® Digital 16.48 - 17.18 Chemistry of bone agents simulation of the new dual/triple-head Mediso Dry Bath for the Preparation of Ines Melo AnyScan SPECT system for acquisition Radiopharmaceuticals that Require Heating King's College London protocol optimisation and image correction Shazmeen Hansrod, Thomas Wan, Megan Sophia Pells1,2, David M. Cullen1, Andrew P. Longworth, Harry Grover, Beverley Ellis Robinson2,3,4, Ben Pietras1, Nick Calvert4, Daniel Manchester University NHS Foundation Trust, Deidda2, Andrew Fenwick2, Kelley Ferreira2, David Manchester, United Kingdom Hamilton4, Warda Heetun2, George Needham1, Emma Page4, Emlyn Price1, Jill Tipping4 1The University of Manchester, Manchester, United Kingdom. 2National Physical Laboratory, Teddington, United Kingdom. 3University of Manchester, Manchester, United Kingdom. 4The Christie NHS Foundation Trust, Manchester, United Kingdom

17.15 - 17.45 17.10 - 17.21 35 - Optimising the Energy Window for SeHCAT 17.10 - 17.21 47 - Supramolecular cages for binding 17.18 - 17.48 Imaging of Bone Agents 99m Ana Queiroz and Graça Paixão Counting using Geant4 Monte Carlo radiolabelled anions: [ Tc]TcO4– and (InHealth) and (Birmingham) Simulations. [18F]SO F–. Gregory James, Joseph O'Brien, Bill Thomson 3 Vincent Nail1, Benjamin Burke1, William City Hospital, Birmingham, United Kingdom Grantham2, David Roberts1, Isaline Renard1, Paul Lusby2, Stephen Archibald1 1University of Hull, PET Research Centre, Hull, United Kingdom. 2University of Edinburgh, Department of Chemistry, Edinburgh, United Kingdom 17.21 - 17.32 36 - Building and validating a full gamma 17.21 - 17.45 Radiopharmcy Group AGM camera model in Geant4 for research applications. Gregory James, Joseph O'Brien, Bill Thomson City Hospital, Birmingham, United Kingdom 17.32 - 17.43 37 - Development of a Bespoke Cardiac Prototype Phantom for Dynamic Imaging Sarah Williams, Kirsty Jones, Craig Paterson, Jamie Robinson, Nicholas Goodfield Glasgow Royal Infirmary, Glasgow, United Kingdom 17.45 Close Close Close Close 19.30 Awards Dinner Awards Dinner Awards Dinner Awards Dinner WEDNESDAY 20TH MAY

HALL 3 HALL 4 HALL 11C HALL 11B 8.30 REGISTRATION OPENS 9.00 - 10.30 SESSION 14 - PET/CT masterclass 9.00 - 10.30 SESSION 15 - General Nuclear 9.00 - 10.30 Session 17 - Theragnostics 9.00 - 10.30 session 16- Dosimetry Medicine Chairs: TBC Chairs: TBC Chairs: TBC Chairs: TBC 09.00 - 09.25 PET-CT in immunotherapy 09.00 - 09.11 61 - Terminology used when reporting 09.00 - 09.11 74 - Radium Dichloride ([223Ra] RaCl2) 09.00 - 09.11 88 - Uncertainty calculations for 90Y SIRT absorbed Prof Gary cook Dual Energy X-ray Absorptiometry in therapy for bone metastatic castrate resistant doses based on the EANM guidance King's College London Premature Ovarian Insufficiency : Potential survival advantage Allison Craig1,2, Iain Murray1,2, Ana Denis-Bacelar3, Patients. when used earlier in the treatment pathway Jonathan Gear1,2, Lucy Hossen4, Annelies Maenhout5, Harini Fernando1,2, Amy Eccles1,2 Adrian Ho, Peter Jarvis, Ganesh Vigneswaran, Nasir Khan5, Glenn Flux1,2 1Kings College, London, United Kingdom. Sally-Anne Shelton, Francis Sundram 1Royal Marsden NHSFT, Sutton, United Kingdom. 2The 2Guys and St Thomas' Trust, London, Department of Nuclear Medicine, University Institute of Cancer Research, London, United Kingdom. United Kingdom Hospital Southampton, Southampton, United 3National Physical Laboratory, Teddington, United Kingdom Kingdom. 4Royal Brompton & Harefield NHSFT, London, United Kingdom. 5Chelsea & Westminster NHSFT, London, United Kingdom

09.25 - 09.50 PET/CT and PET/MRI in head and neck 9.11-09.22 62 - Role of Bone SPECT/CT in the post- 9.11-09.22 75 - Auger electron emitter radionuclide 09.11-09.22 89 - Variation in the lesion absorbed doses calculated malignancy operative management of children with therapy: In-vitro study of thallium-201 (201Tl) using different methodologies for outlining and partial Dr Teresa Szyszko Slipped Upper Femoral Epiphysis. kinetics and toxicity in breast and prostate volume correction for the SELIMETRY study Kings College London Avyay Sharma1, Sabyasachi cancer cells. Jan Taprogge1,2, Natalie Cooper-Rayner1, Jonathan Bandyopadhyay2, James Kyle3, Eleonora Katarzyna Osytek1, Alex Rigby1, Samantha Gear1,2, Iain Murray1,2, Francesca Leek1, Sarah Manca2, Maryam Jessop2, Nitasha Terry1, Gareth Smith2, Vincenzo Abbate3, Philip Chittenden1,2, Rebecca Gregory3, Andrew Fenwick4, Jill Singh2, Sabina Dizdarevic2 Blower1 Wevrett5, James Scuffham4,5, Jill Tipping6, Brian Murby6, 1Brighton College, Brighton, United 1School of Biomedical Engineering and Imaging Steve Jeans6, Martha Stuffins5, Sofia Michopoulou7, Kingdom. 2Department of Nuclear Sciences, King’s College London, London, Matthew Guy7, Darren Morgan8, Aida Hallam8, David Hall9, Medicine & Clinical Imaging, Brighton & United Kingdom. 2Theragnostics Limited, 2 Heather Polydor9, Colin Brown10, Gerry Gillen10, Nathan Sussex University Hospitals NHS Trust, Arlington Square, Bracknell, United Kingdom. Dickinson11, Sarah Brown12, Jonathan Wadsley13, Glenn Brighton, United Kingdom. 3Department 3School of Population Health and Flux1,2 of Trauma & Orthopaedics, Brighton & Environmental Sciences, King’s College 1Royal Marsden Hospital NHSFT, London, United Sussex University Hospitals NHS Trust., London, London, United Kingdom Kingdom. 2Institute of Cancer Research, London, United Brighton, United Kingdom Kingdom. 3Barts Health NHS Trust, London, United Kingdom. 4National Physical Laboratory, Teddington, United Kingdom. 5Royal Surrey County Hospital NHS Foundation Trust, Guildford, United Kingdom. 6The Christie NHS Foundation Trust, Manchester, United Kingdom. 7University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. 8Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom. 9University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom. 10NHS Greater Glasgow and Clyde, Glasgow, United Kingdom. 11Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 12CTRU, University of Leeds, Leeds, United Kingdom. 13Weston Park Hospital, Sheffield, United Kingdom 09.50 -10.15 F18 FDG PET/CT for cervical carcinoma: Is 09.22 - 09.33 63 - 1ST STUDENT PRIZE Paediatric 09.22 - 09.33 76 - Factors that influence survival in patients 09.22 - 09.33 90 - Feasibility and accuracy of single-time-point it underutilized? gastric emptying: Factors predictive of receiving Radium-dicholoride [223Ra] RaCl2 dosimetry following 223Ra therapy incorporating a Dr Alan Klitzke delayed gastric emptying and clinical therapy – Real world evidence from a single population pharmacokinetic model ACNM President, Roswell Park outcomes at 2 years follow-up UK centre. Jan Taprogge1,2, Iain Murray1,2, Glenn Flux1,2 Comprehensive Cancer Center, Buffalo, New Maryam Hussein1, Esme Poole1, Vinod Peter Jarvis, Adrian Ho, Ganesh Vigneswaran, 1Royal Marsden Hospital NHSFT, Sutton, United Kingdom. York Kolimarala2, Mich Lajeunesse2, Efrem Sally-Anne Shenton, Francis Sundram 2Institute of Cancer Research, London, United Kingdom Eren3, Zia Saad3, Francis Sundram3, University Hospital Southampton, Southampton, Nadeem Ahmad Afzal2 United Kingdom 1University of Southampton, Southampton, United Kingdom. 2Southampton Children's Hospital, Southampton, United Kingdom. 3University Hospital Southampton, Southampton, United Kingdom

10.15 -10.26 59 - The clinical impact of FDG PET in the 09.33 - 09.44 64 - Evaluating Image Quality of 09.33 - 09.44 77 - Identifying Prognostic and Response 09.33 - 09.44 91 - Hybrid voxel dosimetry of a bone scan for the diagnosis and clinical management of anti- [123I]Iodine-DaTSCAN Relative to Markers in Radium Therapy: Bone Scan SOLLID trial neutrophil cytoplasmic antibodies- Administered Dose Quantification and Assessment of Blood Dominic Rushforth, Jonathan Gear, Paul Gape, Jan associated vasculitis (Wegener's Amy Eccles, Ibtisam Musi, André Nunes, Markers Taprogge, Iain Murray, Carla Abreu, Glenn Flux vasculitis) Mohammed Azmat James Gray, James Scuffham, Vineet Prakash, The Royal Marsden NHS Foundation Trust, Sutton, United Stefan Voo1, Michael Kemna2, Jan Willem Guy's and St. Thomas' NHS Foundation Ralf Clauss, Manu Shastry Kingdom Cohen Tervaert2, Jamshed Bomanji1 Trust, London, United Kingdom Royal Surrey County Hospital, Guildford, United 1University College London Hospital, Kingdom London, United Kingdom. 2Maastricht University Medical Centre, Maastricht, Netherlands 09.44 - 09.55 65 - An Audit of DMSA scans at a busy 09.44 - 09.55 78 - An assessment of the efficacy of Yittrium- 09.44 - 09.55 92 - Errors arising from S-values for dosimetry of DGH 90 colloid (Y-90) radiosynovectomy using paediatric radionuclide therapies with 131I and 177Lu Manish Pandit, Lucy Berwick, Joseph Western Ontario and McMaster Universities Ruby Callister1,2, Jonathan Gear2, Antigoni Divoli2, Glenn O'Brien Arthritis Index (WOMAC) values Flux2 SWBH, Birmingham, United Kingdom Lois Collins, Paul Ryan, Noelle Blakeman, 1St George's University Hospitals NHS FT, London, United Beverley Martin, David Simpson Kingdom. 2The Royal Marsden NHS FT, London, United Medway NHS Foundation Trust, Gillingham, Kingdom United Kingdom

09.55 -10.06 66 - Octreoscan Audit: Is the 48-hour 09.55 -10.06 79 - Reassessing the risk of skeletal related 09.55 -10.06 93 - Investigating the Suitability of [68Ga] PSMA PET/CT Image Necessary? events following [223Ra] RaCl2 therapy in for a Large-Scale Epidemiological Trial in Diagnostic Ayah A Nawwar, Julian Kabala, Randeep metastatic castrate resistant prostate cancer. Nuclear Medicine – Initial Results from the SOLLID Trial Kulshrestha Hajira Ilyas, Haseeb Ahmed, Amy Eccles, Fahim Paul Gape1,2, Dominic Rushforth1,2, Carla Abreu1, Iain University Hospitals Bristol, Bristol, United Ul-Hassan, Nicolas Eftychiou, Val Lewington Murray1,2, Jonathan Gear1,2, Glenn Flux1,2 Kingdom Guy's and St.Thomas' NHS Foundation Trust, 1The Royal Marsden NHS Foundation Trust, London, London, United Kingdom United Kingdom. 2The Institute of Cancer Research, London, United Kingdom 10.06 - 10.17 67 - Added diagnostic value of CT 10.06 - 10.17 80 - Investigation of Quantitative Metrics in 10.06 - 10.17 94 - Validation of an Individual approach to Molecular attenuation correction in myocardial [177Lu] Lu-DOTA-TATE SPECT/CT and Radiotherapy Dosimetry using 3D printed phantoms perfusion imaging. [68Ga] Ga-DOTA-TATE PET/CT Scans to Ben Pietras1, Sophia Pells1,2, Nick Calvert3, Andy Namra Asghar1, Humayun Bashir1, Predict Treatment Response in Robinson2, George Needham1, Dave Cullen1, Emma Aamna Hassan1, Saima Riaz2,3 Neuroendocrine Tumours Page3, Jill Tipping3 1Shaukat Khanum Memorial Cancer Amelia Perry Lefteris Livieratos, Val Lewington 1The University of Manchester, Manchester, United Hospital and Research Centre, Lahore, Guy's and St Thomas' NHS Foundation Trust, Kingdom. 2The National Physical Laboratory, Teddington, Pakistan. 2Shaukat Khanum Memorial London, United Kingdom. King's College United Kingdom. 3The Christie research hospital, Cancer Hospital and Research Centre, London, London, United Kingdom Manchester, United Kingdom Lahore, Palestine. 3UCLH, London, United Kingdom 10.17 - 10.28 81 - Incidence of raised HbA1c of ≥ 42 10.17 - 10.28 95 - Improved prediction of haematological toxicity mmol/mol (Normal ≤41 mmol/mol) in patients during [177Lu] Lu-DOTA-TATE therapy by optimising with Neuroendocrine Tumour (NET) receiving serial SPECT/CT red marrow dosimetry peptide receptor radionuclide therapy (PRRT) Emma Page1, Jill Tipping1, Nick Calvert1, David Hamilton1, with [177Lu]Lu-DOTA-TATE at Guy’s and St. David Cullen2, Sophia Pells2, George Needham2, Ben Thomas’ NHS Foundation Trust. Pietras2, Peter Julyan1 Hajira Ilyas, Amy Eccles, Nicolas Eftychiou, 1The Christie NHS Foundation Trust, Manchester, United Haseeb Ahmed, Fahim Ul-Hassan, Val Kingdom. 2The University of Manchester, Manchester, Lewington United Kingdom Guy's and St.Thomas's NHS, London, United Kingdom

10.28 - 11.00 Refreshment break Refreshment break Refreshment break Refreshment break 11.00 - 12.30 SESSION 18 PARATHYROID 11.00 - 12.30 SESSION 19 - PET/CT in NHS England SESSION 20 Oncology PET/CT SESSION 21 Radiation protection MASTERCLASS and proferred papers Chairs: TBC Chairs: TBC Chairs: TBC Chairs: TBC 11.00 - 11.25 Parathyroid Scintigraphy revisited: planar 11.00 - 11.30 Implementing PET CT service 11.00 - 11.11 82 - Response Assessment of Ewing’s 11.00 - 11.11 96 - Variation in external dose rates with time for a and SPECT-CT development into the NHS in England Sarcoma Family of Tumours (ESFT) by [18F] [177Lu] PSMA patient over multiple treatment cycles. Dr Qaisar Hussain Siraj Dr Wai Lup Wong and Ms Nicola FDG PET/CT - Indian experience Nathaniel Scott1, Anne-Marie Stapleton2, Carolyn Lory1, Farwania Hospital Kuwait McCulloch Amrita Tiwary Vyas1, Ajay Gopal Vyas2, Man Sara Gomes-Santos1, Daniel McGowan1,3, Yong Du1,4 Mount Vernon Hospital and NHS England Mohan Mehndiratta1 1GenesisCare, Windsor, United Kingdom. 2Royal Surrey 1Janakpuri Super speciality Hospital New Delhi, County Hospital NHS Foundation Trust, Guildford, United Delhi, India. 2Max Hospital Vashali, Ghaziabad, Kingdom. 3University of Oxford, Oxford, United Kingdom. India 4The Royal Marsden NHS Foundation Trust, London, United Kingdom

11.25 - 11.50 SPECT-CT and PET-CT Parathyroid 11.30 - 11.41 68 - An evaluation of whether 11.11 - 11.22 83 - Interobserver reliability in the 11.11 - 11.22 97 - Management of a Lutetium-177 PSMA therapy Imaging PET/CT changes the restaging of quantitative assessment of [99mTc]-labelled patient undergoing surgery Dr Richard Graham biochemically recurrent prostate anti-Programmed Death-Ligand 1 (PD-L1) Matthew Galloway, Emily Aveyard, Christopher Pickles, Royal United Hospital, Bath cancer following prior imaging with at SPECT in non-small cell lung cancer. James Cullis least two other modalities. Daniel Johnathan Hughes1, Gitasha Chand1,2, UHCW NHS Trust, Coventry, United Kingdom Monique Vekeria, Randeep Kulshrestha, Hong Hoi Ting2, Victoria Warbey1, Vicky Goh1, Amarnath Challapalli Gary Cook1 Bristol Royal Infirmary, Bristol, United 1Department of Cancer Imaging, School of Kingdom Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. 2Department of Research and Development, NanoMab Technology Limited, Shanghai, China 11.50 - 12.15 Parathyroid Imaging with 18F-Choline PET- 11.41 - 11.52 69 - Diagnostic accuracy of [68Ga] Ga- 11.22 - 11.33 84- Identification of specific SUVmax ratios 11.22 - 11.33 98 - Generating retrospective patient specific radiation CT PSMA PET/CT in patients with enhances diagnostic accuracy for staging of restrictions following [177Lu] Lu-PSMA therapy in an Prof Drazen Huic recurrent prostate cancer and intrathoracic nodes in lung cancer outpatient setting President of Croatian Society of Nuclear correlation with clinical and Nadia Matei, Justyn Jeon, James Myerson, Nigel Anne-Marie Stapleton1, Nathaniel Scott2, Alexander Medicine, University Hospital Rebro Zagreb, pathological outcomes. Marchbank, Deborah Pencharz Smout1, Sara Gomes-Santos2, Carolyn Lory2, Daniel Croatia Anna Witkowska-Wrobel1, Arman Parsai1, Brighton and Sussex University Hospitals NHS McGowan2,3, Yong Du2,4 Jonathan Shamash2, Jane Sosabowski3, Trust, Brighton, United Kingdom 1Royal Surrey NHS Foundation Trust, Guildford, United Jennifer Young3, Cindy Leung1, Busola Kingdom. 2GenesisCare, Windsor, United Kingdom. Ade-Ojo4, Anju Sahdev5, Rebecca 3University of Oxford, Oxford, United Kingdom. 4Royal Gregory1, Ewa Nowosinska1 Marsden NHS Foundation Trust, London, United Kingdom 1Nuclear Medicine Barts Health, London, United Kingdom. 2Medical Oncology Barts Health, London, United Kingdom. 3Centre of Molecular Oncology, QMUL, London, United Kingdom. 4Radiopharmacy, Barts Health, London, United Kingdom. 5Radiology, Barts Health, London, United Kingdom

12.15 - 12.26 60 - An analysis of a new parathyroid 11.52 - 12.03 70 - [68Ga]Prostate Specific Membrane 11.33 - 11.44 85 - Utility of [18F] FDG in the management of 11.33 - 11.44 99 - Optimisation of 177Lu therapy administration scintigraphy protocol evaluating the Antigen or [18F] : When & multiple myeloma Richard Fernandez1, Amelia Perry2, Peter Croasdale1, contribution of the different scintigraphic Why - A Comparative Review of early Phei Shan Chuah, Rashika Fernando, Ruth Jessica Johnson1, Sasha Rai1, Nicolas Eftychiou2 components: planar, SPECT, SPECT/CT clinical experience in a UK centre Brown, Gillian Brearton, Stephen Hawkins, 1Guy's & St Thomas' NHS Foundation Trust, London, and surface rendering, in comparison with Mellanie-Anne Didier1,2, Ruth Brown3, Nagabushan Seshadri United Kingdom. 2King's College London, London, United histopathological outcomes. Sobhan Vinjamuri3 Royal Liverpool University Hospital, Liverpool, Kingdom Hajira Ilyas, Charlotte Fowler 1University Hospital of the West Indies, United Kingdom Guy's and St.Thomas' NHS Foundation Trust, Kingston, Jamaica. 2Royal Liverpool London, United Kingdom University Hospital, Liverpool, United Kingdom. 3Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

11.00 - 11.25 Intravenous contrast for SPECT-CT 12.03 - 12.14 71 - Inter-reader reliability of [68Ga] Ga- 11.44 - 11.55 86 - 82 - Tumour heterogeneity changes in 11.44 - 11.55 100 - The Introduction and optimisation of semi- Parathyroid Imaging THP-PSMA PET/CT interpretation in arginine deprivation treatment response in automatic dispensing in PET Dr Richard Graham patients with prostate cancer mesothelioma using FDG PET data Sorcha Curry1, Aidan Griffiths2, Sofia Pereira1, John Royal United Hospital, Bath Gary Cook1, Dimitris Priftakis2, Marie Teresa Szyszko1, Muhammad Siddique2, Paul Joemon1, Armidita Jacob1, Alyss Harman1, Jane Mackewn1 Meagher2, Raymond Endozo2, Jamshed Bassett3, Christopher Rookyard2, Peter 1King’s College London & Guy’s and St Thomas’ PET Bomanji2, Asim Afiq2 Szlosarek4, Vicky Goh2, Gary Cook2,1 Centre, School of Biomedical Engineering and Imaging 1King's College London, London, United 1KCL and GSTT PET Centre, London, United Sciences, King’s College London, London, United Kingdom. Kingdom. 2UCLH, London, United Kingdom. 2KCL Division of Imaging Sciences 2Guy's and St Thomas' NHS Foundation Trust, London, Kingdom and Biochemical Engineering, London, United London, United Kingdom Kingdom. 3Statsconsultancy, Amersham, United Kingdom. 4Barts Cancer Institute, London, United Kingdom 12.14 - 12.25 72 - Initial Experience of [18F] PSMA 11.55 - 12.06 87 - 69 - Incidental breast lesions in PET/CT: 11.55 - 12.06 101 - Contamination Accidents with 99mTc, 18F, 90Y, 123I PET/CT Imaging in a District General evidence of follow-up & outcome in single and 131I. Potential skin dose values to the gloved hand Hospital centre 2013-2019 and the protective value of different gloves using the Rob Foley, Stewart Redman, Richard Salma Audi, Malavika Nathan Delacroix droplet model and a new model for a ‘droplet’ Graham, David Little Royal Free Hospital, London, United Kingdom calculated with VARSKIN v6.2. Royal United Hospital, Bath, United Bill Thomson Kingdom Physics and Nuclear Medicine, Birmingham, United Kingdom

12.25 - 12.36 73 - Diagnostic efficacy of [18F] PSMA 12.06 - 12.17 102 - Estimation of effective dose to the sensitive PET/CT in early detection of epithelial layer of the lens of the eye after biochemically recurrent carcinoma contamination with common prostate Matthew Memmott Amrita Tiwary Vyas1, Ajay Gopal Vyas2, Manchester University Hospitals NHS Foundation Trust, Pankaj Dougall3, Abhishek Gupta2, Man Manchester, United Kingdom Mohan Mehndiratta1 1Janakpuri Superspeciality Hospital, Govt of NCT Delhi, Delhi, India. 2Max Super Speciality Hospital , Vaishali, Ghaziabad, Ghaziabad, India. 3Max Super Speciality Hospital, Delhi, India

12.17 - 12.28 103 - Simplifying committed dose calculations for carers and comforters Alexander Smout, James Scuffham Royal Surrey County Hospital, Guildford, United Kingdom

12.30 - 13.30 Lunch break 12.30 - 13.30 Lunch break 12.30 - 13.30 12.30 - 13.30 Lunch break 13.30 - 15.35 FINAL PLENARY SESSION Chairs: 13.30 - 14.20 PET-CT /Infection Imaging Prof Iain Lyburn and Prof Kevin Davies Gloucestershire Hospitals NHS FT/Cobalt Health and Brighton and Sussex Medical School

14.20 - 14.35 PRIZE GIVING 14.35 - 14.50 PRESIDENT HANDOVER 14.50 - 15.35 HIGHLIGHTS LECTURE Dr Gill Vivian1 and Prof Richard Lawson2 2Central Manchester Nuclear Medicine 1 Centre and King's College Hospital 15.35 Close